Trial

High-flow nasal cannula oxygen compared to standard oxygen therapy is not associated with a significant reduction in mortality in patients with respiratory failure due to COVID-19 - The SOHO-Randomized Clinical Trial |  Medicine in 2 Minutes

High-flow nasal cannula oxygen compared to standard oxygen therapy is not associated with a significant reduction in mortality in patients with respiratory failure due to COVID-19 – The SOHO-Randomized Clinical Trial | Medicine in 2 Minutes

1. In this randomized controlled trial, among 711 patients with respiratory failure due to COVID-19, day 28 mortality was 10% in the high-flow oxygen group and 11% in the oxygen therapy group standard. 2. The intubation rate was significantly lower with high flow oxygen (45%) than with standard oxygen (53%). Level of evidence assessment: 1 …

High-flow nasal cannula oxygen compared to standard oxygen therapy is not associated with a significant reduction in mortality in patients with respiratory failure due to COVID-19 – The SOHO-Randomized Clinical Trial | Medicine in 2 Minutes Read More »

New Alzheimer's drug slows mental decline by 27% in clinical trial

New Alzheimer’s drug slows mental decline by 27% in clinical trial

Japanese pharmaceutical company Eisai and its partner, Cambridge-based Biogen, announced that their drug slowed cognitive decline in Alzheimer’s disease in a global trial. The drug, an antibody called lecanemab, slowed the rate of cognitive decline in volunteers by 27% compared to those given a placebo in the large late-stage trial. The companies plan to present …

New Alzheimer’s drug slows mental decline by 27% in clinical trial Read More »

Results from the pivotal Insulin-Only Bionic Pancreas trial, which were presented at the ADA's 82nd Scientific Sessions, are published this week in the New England Journal of Medicine.

Results from the pivotal Insulin-Only Bionic Pancreas trial, which were presented at the ADA’s 82nd Scientific Sessions, are published this week in the New England Journal of Medicine.

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) right to use for investigative purposes. Not available for sale. Pending 510k permission. CONCORD, Mass., September 30, 2022 /PRNewswire/ — Beta Bionics, Inc. — Results from the pivotal multicenter randomized Insulin-Only Bionic Pancreas (IO BPPT) trial, which were presented in …

Results from the pivotal Insulin-Only Bionic Pancreas trial, which were presented at the ADA’s 82nd Scientific Sessions, are published this week in the New England Journal of Medicine. Read More »

Can a daily nutritious shake prevent memory loss?  A new trial aims to answer that and is looking for volunteers.  - The Boston Globe

Can a daily nutritious shake prevent memory loss? A new trial aims to answer that and is looking for volunteers. – The Boston Globe

After years of studying the way Americans eat and the myriad health problems that stem from crummy diets, lead researcher Susan Roberts said it’s time to get pragmatic. “We can be purists and say everyone should have the perfect diet, but the reality is that for most people it won’t work for them,” said Roberts, …

Can a daily nutritious shake prevent memory loss? A new trial aims to answer that and is looking for volunteers. – The Boston Globe Read More »

Randomized multicenter trial of a bionic pancreas in type 1 diabetes |  NEJM

Randomized multicenter trial of a bionic pancreas in type 1 diabetes | NEJM

The full names and academic degrees of the authors are as follows: Steven J. Russell, MD, Ph.D., Roy W. Beck, MD, Ph.D., Edward R. Damiano, Ph.D., Firas H. El-Khatib, Ph.D., Katrina J. Ruedy, MSPH, Courtney A. Balliro, RN, CDCES, CRN-BC, Zoey Li, MS, Peter Calhoun, Ph.D., R. Paul Wadwa, MD, Bruce Buckingham, MD, Keren Zhou, …

Randomized multicenter trial of a bionic pancreas in type 1 diabetes | NEJM Read More »

Sandoz Announces Further Progress in its Biosimilars Portfolio, with the Publication of Positive Results from the Integrated Phase I/III Clinical Trial of Denosumab

Sandoz Announces Further Progress in its Biosimilars Portfolio, with the Publication of Positive Results from the Integrated Phase I/III Clinical Trial of Denosumab

The ROSALIA study met the primary endpoints, confirming that the proposed biosimilar denosumab matches the reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in postmenopausal women with osteoporosis Osteoporosis is responsible for 8.9 million bone fractures a year, including debilitating hip fractures – a number that is expected to rise dramatically over …

Sandoz Announces Further Progress in its Biosimilars Portfolio, with the Publication of Positive Results from the Integrated Phase I/III Clinical Trial of Denosumab Read More »